NEWS - Oct 27, 2017 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
NEWS - Jun 28, 2017 Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program Read more
NEWS - Jun 21, 2017 Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics Read more
NEWS - Jun 15, 2017 Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors Read more
NEWS - May 18, 2017 Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company Read more
NEWS - Apr 13, 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder Read more
NEWS - Feb 15, 2017 Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference Read more
NEWS - Jan 25, 2017 Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone Read more
